A Study of BMS-986482 Alone or as Combination Therapy in Participants With Advanced Solid Tumors
Phase 1/2
413
about 3.9 years
18+
7 sites in CA, CO, NC +3
What this study is about
Researchers are testing the safety and effectiveness of BMS-986482 alone or with other medications in people with advanced solid tumors. The trial will last for about 1 year and a half, involving approximately 400 participants.
Simplified from trial records by PatientMatch.
What you may be asked to do
- 1.Take BMS-986482
- 2.Take Bevacizumab
- 3.Take Nivolumab and rHuPH20
- +1 more
Participation Burden
What's physically and logistically required of participants.
Requires travel to a study site
How treatment is administered
You are randomly assigned, but you will know your treatment.
Extracted study details
Pulled from the trial record to show what is being tested and what the study is measuring.
bevacizumab, nivolumab (Immune checkpoint inhibitor; blocks PD-1 receptor on T cells), hyaluronidase, Antineoplastic Agent [TC] (Antibody-Receptor Interactions)
infusion
Primary: Number of participants with AEs leading to discontinuation as assessed by NCI-CTCAE v5.0, Number of participants with AEs meeting protocol-defined Dose-Limiting Toxicity (DLT) criteria as assessed by NCI-CTCAE v5.0, Number of participants with Adverse Events (AEs) as assessed by National Cancer Institute -Common Terminology Criteria for Adverse Events version 5.0 (NCI-CTCAE v5.0), Number of participants with Serious AEs (SAEs) as assessed by NCI-CTCAE v5.0
Secondary: Area under the concentration-time curve in one dosing interval (AUC(TAU)), Concentration at the end of infusion (Cmax), Overall Response Rate (ORR) per Response Evaluation Criteria in Solid Tumors (RECIST v1.1) as assessed by Investigator, Time of maximum observed concentration (Tmax)